 |
 |

Very Early Exposure to Erythromycin and Infantile Hypertrophic Pyloric Stenosis
William O. Cooper, MD, MPH;
Marie R. Griffin, MD, MPH;
Patrick Arbogast, PhD;
Gerald B. Hickson, MD;
Shiva Gautam, PhD;
Wayne A. Ray, PhD
Arch Pediatr Adolesc Med. 2002;156:647-650.
Objective To assess the link between very early erythromycin exposure and pyloric
stenosis in young infants.
Design Retrospective cohort study.
Participants and Methods Medicaid or TennCare (Tennessee's program for Medicaid enrollees and
uninsured individuals) births in Tennessee from 1985 to 1997. Cases of infants
with a hospital discharge diagnosis of pyloric stenosis and an associated
surgical procedure code were used. Erythromycin exposure and other antibiotic
exposure between 3 and 90 days of life were identified from prescription files.
Main Outcome Measures Hospital discharge diagnosis of pyloric stenosis, and an associated
surgical procedure code.
Results Of 933 239 births in Tennessee during the study period, 314 029
were enrolled in Medicaid. Among these infants, 804 (2.6/1000 infants) met
the criteria for pyloric stenosis. Very early exposure to erythromycin (between
3 and 13 days of life) was associated with a nearly 8-fold increased risk
of pyloric stenosis (adjusted incident rate ratio, 7.88; 95% confidence interval,
1.97-31.57). No increased risk of pyloric stenosis was seen in infants exposed
to erythromycin after 13 days of life or in infants exposed to antibiotics
other than erythromycin.
Conclusions The significant increase in pyloric stenosis in children with very early
exposure to erythromycin is consistent with reports of other investigators.
The risks and benefits of erythromycin should be weighed carefully prior to
initiating such therapy in young infants.
From the Department of Pediatrics, Division of General Pediatrics (Drs
Cooper and Hickson), and the Department of Preventive Medicine, Divisions
of Pharmacoepidemiology (Drs Griffin and Ray) and Biostatistics (Drs Arbogast
and Gautam), Vanderbilt University, Nashville, Tenn.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Vomiting in Children: Reassurance, Red Flag, or Referral?
Chandran and Chitkara
Pediatr. Rev. 2008;29:183-192.
FULL TEXT
Are young infants treated with erythromycin at risk for developing hypertrophic pyloric stenosis?
Maheshwai
Arch. Dis. Child. 2007;92:271-273.
FULL TEXT
A Randomized Controlled Trial Comparing Three Different Techniques of Nasojejunal Feeding Tube Placement in Critically Ill Children
Phipps et al.
JPEN J Parenter Enteral Nutr 2005;29:420-424.
ABSTRACT
| FULL TEXT
Apnea Is Not Prolonged by Acid Gastroesophageal Reflux in Preterm Infants
Bancalari
Pediatrics 2005;116:1217-1218.
FULL TEXT
Erythromycin as a prokinetic agent in preterm neonates: a systematic review
Patole et al.
Arch. Dis. Child. Fetal Neonatal Ed. 2005;90:F301-f306.
ABSTRACT
| FULL TEXT
Gastroesophageal Reflux in the Preterm Neonate
Jadcherla and Rudolph
NeoReviews 2005;6:e87-e98.
FULL TEXT
Oral Erythromycin Prophylaxis vs Watchful Waiting in Caring for Newborns Exposed to Chlamydia trachomatis
Rosenman et al.
Arch Pediatr Adolesc Med 2003;157:565-571.
ABSTRACT
| FULL TEXT
Erythromycin Linked to Pyloric Stenosis in Very Young Babies
JWatch Pediatrics 2002;2002:8-8.
FULL TEXT
Erythromycin and Pyloric Stenosis
Neuspiel
AAP Grand Rounds 2002;8:44-45.
FULL TEXT
Erythromycin Linked to Pyloric Stenosis in Very Young Babies
JWatch General 2002;2002:4-4.
FULL TEXT
|